This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Lupin consolidated Sep 2026 quarter: revenue up 11%, net profit down 22%
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated results for the quarter ended September 30, 2026 show revenue from operations up 11.1% to Rs 78,272.6 million from Rs 70,475.1 million a year earlier; net profit fell 22.2% to Rs 11,553.0 million from Rs 14,848.3 million. Margin before interest, tax, depreciation and amortisation fell from 33.2% to 26.1%. Standalone quarter net profit was a Rs 59.1 million loss after a Rs 769.3 million impairment.
Revenue growth is positive, but lower net profit and a 7.1 percentage point margin decline may pressure earnings sentiment and the stock.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹7,827 Cr | ₹7,048 Cr | +11.1% |
| Operating profit | ₹1,453 Cr | ₹1,917 Cr | −24.2% |
| Profit after tax | ₹1,155 Cr | ₹1,485 Cr | −22.2% |
| EBITDA margin | 26.1% | 33.2% | −7.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.